Tisdag 17 November | 13:07:40 Europe / Stockholm
Est. tid*
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-21 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2026-05-20 - Årsstämma
2026-02-26 - Bokslutskommuniké 2025
2026-01-19 - Split ONCIN 100:1
2026-01-08 - Extra Bolagsstämma 2026
2025-08-20 - Kvartalsrapport 2025-Q2
2025-06-26 - Årsstämma
2025-05-21 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2025-02-26 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-10 - Extra Bolagsstämma 2024
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-30 - Split ONCIN 100:1
2024-05-29 - Kvartalsrapport 2024-Q1
2024-05-24 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2024-05-23 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-22 - Kvartalsrapport 2023-Q1
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2023-02-16 - Bokslutskommuniké 2022
2022-11-15 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2022-04-28 - Årsstämma
2022-02-16 - Bokslutskommuniké 2021
2022-01-06 - Extra Bolagsstämma 2022
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-19 - Kvartalsrapport 2021-Q1
2021-03-22 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2021-03-19 - Årsstämma
2021-02-10 - Bokslutskommuniké 2020
2020-12-09 - Extra Bolagsstämma 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-19 - Kvartalsrapport 2020-Q1
2020-03-17 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2020-03-16 - Årsstämma
2020-02-11 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-19 - Kvartalsrapport 2019-Q2
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-14 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2019-03-13 - Årsstämma
2019-02-19 - Bokslutskommuniké 2018
2018-11-13 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-15 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2018-05-15 - Kvartalsrapport 2018-Q1
2018-05-14 - Årsstämma
2018-03-09 - Extra Bolagsstämma 2018
2018-02-13 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-23 - Kvartalsrapport 2017-Q1
2017-03-23 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2017-03-22 - Årsstämma
2016-06-22 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2016-06-21 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning ONCIN 0.00 NOK
2015-06-22 - Årsstämma
LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Oncoinvent är ett radiofarmaceutiskt bolag i klinisk fas som utvecklar behandlingar för solida cancerformer. Teknikplattformen är fokuserad på användningen av alfa-emitterande radionuklider för att leverera strålning direkt till cancerceller. Bolagets produktkandidat, Radspherin®, är en alfa-strålterapikandidat designad för lokal behandling av cancer som har spridit sig till kroppshåligheter. Oncoinvent har sitt huvudkontor i Oslo.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Oncoinvent ASA: Radspherin[®] shows favorable safety profile in the first interim safety readout from the ongoing randomized phase 2 trial in ovarian cancer

2026-11-17 07:34:01
  • Radspherin® continues to show a favorable safety and tolerability profile
  • No serious adverse event in the trial was assessed as possibly related to Radspherin®
  • Independent Data Monitoring Committee recommended continuing the trial without modification
  • Interim efficacy readout on track for April 2027

Oslo, Norway, 17 November 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that no serious adverse event was related to Radspherin® in the interim safety analysis of its ongoing randomized Phase 2 trial (RAD-18-003, NCT06504147) in patients with peritoneal metastases from advanced ovarian cancer. These are the first randomized, controlled safety data for Radspherin®.

As of the data cut-off on 30 October 2026, 74 patients had been randomized (2:1 - Radspherin® : Control). The safety analysis set comprised 56 primary ovarian cancer patients who achieved complete surgical resection after neoadjuvant chemotherapy, of whom 40 received a single intraperitoneal dose of Radspherin® (7 MBq) after surgery in addition to standard of care, and 16 received standard of care alone.

At this stage in the trial, there were no serious adverse events considered related to Radspherin®, no deaths, and no adverse events leading to discontinuation. The proportion of patients with treatment-emergent adverse events (TEAEs, events reported on or after treatment start, regardless of cause) was similar in both arms. The safety profile of Radspherin® remains consistent with previously published clinical data.

The majority of TEAEs in the experimental arm were considered unrelated to Radspherin® and were consistent with the underlying disease and expected postoperative clinical course. At the patient level, the most frequent TEAEs in the experimental arm were constipation, anemia, abdominal pain, nausea and hypokalemia. A total of 10 events reported in five patients (12.5%) were considered as possibly related to Radspherin®. These latter events were all mild or moderate (Grade 1 or 2) and included vomiting (2), nausea, abdominal pain, constipation, headache, dizziness, fatigue, anemia, and decreased lymphocyte count (one event each).

The trial's Independent Data Monitoring Committee reviewed the unblinded safety data on 13 November 2026 and recommended that the trial continue without modification.

"Women in this trial have just been through neoadjuvant chemotherapy and major abdominal surgery, so any treatment added afterwards must be well tolerated," said Professor Ignace Vergote, gynaecologic oncologist and Professor Emeritus at the Catholic University Leuven, Belgium. "It is encouraging to now see this in randomized data. The adverse events observed in both arms of the trial are what we would expect in patients recovering from this type of surgery, which is reassuring for patients and their physicians."

These randomized data are consistent with the safety profile seen in previous Radspherin® trials: the safety run-in cohort of this trial, completed in March 2025, the Phase 1 trial in recurrent ovarian cancer (RAD-18-001, n=21) and the Phase 1/2a trial in colorectal cancer (RAD-18-002, n=47), in which no dose-limiting toxicity was observed at the recommended dose of 7 MBq [1,2].

"These first randomized data are an important milestone for Oncoinvent and for the Radspherin® program," said Dr Zuzana Jirakova Trnkova, Chief Medical Officer of Oncoinvent. "The safety profile is in line with what we have reported in previous studies, which strengthens our confidence as we move towards the efficacy readout in the spring and readiness for Phase 3. We thank the patients, investigators and site teams who made this possible."

Recruitment in the phase 2 trial is expected to complete in the first half of 2027. The interim efficacy readout, planned for April 2027, will include close to all randomized patients, of whom approximately 40 will have at least nine months of follow-up.

***

Notes on Safety Terminology

  • Adverse event: An unintended medical event reported by a patient during the trial, regardless of whether it is related to the trial drug.
  • Treatment-emergent adverse events: Any unintended medical event that began or worsened after the patient received the first dose of the trial drug, whether or not it was caused by the drug.
  • Serious treatment-emergent adverse events: A major medical event (such as hospitalization or a life-threatening condition) that began or worsened after treatment started, regardless of whether it was linked to the trial drug.

***

[1] Wang, Yun, et al. "First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer." Gynecologic Oncology 204 (2026): 158-164.

[2] Larsen, Stein Gunnar, et al. "First experience with 224Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)." Frontiers in medicine 10 (2023): 1070362.